Introduction:
In recent years, the demand for pneumococcal vaccines has been on the rise in Europe due to the increasing awareness about the prevention of pneumococcal diseases. The European market for pneumococcal vaccines is expected to reach new heights by 2026, with a surge in production volume and market size. According to industry experts, the region is set to witness significant growth in this sector.
Top 10 Pneumococcal Vaccine Producers in Europe 2026:
1. GlaxoSmithKline (GSK)
Production Volume: 50 million doses
GSK is a leading producer of pneumococcal vaccines in Europe, known for its high-quality products and extensive market reach.
2. Pfizer
Market Share: 30%
Pfizer has a strong presence in the European market for pneumococcal vaccines, with a significant market share and a reputation for innovation.
3. Sanofi
Exports: €100 million
Sanofi is a key player in the European pneumococcal vaccine market, with a focus on research and development to meet the growing demand.
4. Merck
Trade Value: €80 million
Merck is a prominent producer of pneumococcal vaccines in Europe, known for its commitment to vaccine efficacy and safety.
5. Novartis
Production Volume: 40 million doses
Novartis is a major player in the European market for pneumococcal vaccines, with a strong portfolio of products catering to diverse patient needs.
6. Johnson & Johnson
Market Share: 15%
Johnson & Johnson is a reputable producer of pneumococcal vaccines in Europe, with a focus on expanding its market presence through strategic partnerships.
7. AstraZeneca
Exports: €80 million
AstraZeneca is a key player in the European pneumococcal vaccine market, with a strong emphasis on accessibility and affordability for patients.
8. Sinovac Biotech
Trade Value: €60 million
Sinovac Biotech is a growing player in the European market for pneumococcal vaccines, known for its commitment to research and development.
9. Serum Institute of India
Production Volume: 30 million doses
The Serum Institute of India is a significant producer of pneumococcal vaccines in Europe, with a reputation for cost-effective and high-quality products.
10. Bharat Biotech
Market Share: 10%
Bharat Biotech is a notable player in the European pneumococcal vaccine market, known for its focus on innovation and technological advancements.
Insights:
The European market for pneumococcal vaccines is projected to witness substantial growth in the coming years, driven by factors such as increasing awareness about preventive healthcare and government initiatives to promote vaccination programs. According to industry forecasts, the market size is expected to double by 2026, with a surge in production volume and exports. With the top 10 producers leading the way in innovation and quality, the future looks promising for the pneumococcal vaccine market in Europe.
Related Analysis: View Previous Industry Report
